TRexBio Closes $26M Series A Extension Funding
- TrexBio, a South San Francisco, CA-based discovery stage biotech company, raised $26M in Series A extension funding
- The round, which brings the total Series A funding raised to $85m, was led by Polaris Partners and Laurion Capital
- In conjunction with the financing, Alexandra Cantley, Ph.D., Partner at Polaris Partners will join the company’s Board of Directors
- Alexander Duncan, Ph.D., Biotech Associate at Laurion Capital Management also joins as a Board Observer
- The company intends to use the funds for the continued expansion of its platform and the advancement of multiple programs through pre-IND activities
- The company is advancing multiple preclinical programs
